Bristol-Myers Squibb Company Ce (CELG-RI) , forward earnings yield 5,000.00%. Graham Number is $32.27.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 0.1 | 0.00 | 0.02 | 0.01 | 984.02% |
| 2017 | 0.3 | 0.00 | 0.02 | 0.01 | 1,011.35% |
| 2018 | 0.1 | 0.00 | 0.02 | 0.01 | 1,033.01% |
| 2019 | 0.1 | 0.00 | 0.01 | 0.01 | 1,014.38% |
| 2020 | 0.0 | 0.00 | 0.01 | 0.01 | 1,165.08% |
| 2021 | 0.0 | 0.00 | 0.01 | 0.01 | 1,277.79% |
| 2022 | 0.0 | -0.01 | 0.01 | 0.01 | 1,843.72% |
| 2023 | 0.0 | 0.00 | 0.01 | 0.00 | 2,547.66% |
| 2024 | 0.0 | 0.00 | 0.01 | 0.00 | 4,896.15% |
| 2025 | 0.0 | 0.00 | 0.01 | 0.00 | 3,449.70% |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $2.65 | $19.43B | $4.46B | 22.9% |
| 2017 | $0.61 | $20.78B | $1.01B | 4.8% |
| 2018 | $3.03 | $22.56B | $4.95B | 21.9% |
| 2019 | $2.01 | $26.15B | $3.44B | 13.2% |
| 2020 | $-3.98 | $42.52B | $-9B | -21.2% |
| 2021 | $3.12 | $46.39B | $6.99B | 15.1% |
| 2022 | $2.95 | $46.16B | $6.33B | 13.7% |
| 2023 | $3.86 | $45.01B | $8.03B | 17.8% |
| 2024 | $-4.41 | $48.3B | $-8.95B | -18.5% |
| 2025 | $3.46 | $48.19B | $7.05B | 14.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $6.26 | $6.26 – $6.26 | $46.89B | $46.89B – $46.89B | 1 |
| 2027 | $6.13 | $6.13 – $6.13 | $45.97B | $45.97B – $45.97B | 1 |
| 2028 | $5.45 | $5.45 – $5.45 | $40.75B | $40.75B – $40.75B | 1 |
| 2029 | $4.91 | $4.91 – $4.91 | $37.07B | $37.07B – $37.07B | 1 |
| 2030 | $4.89 | $4.89 – $4.89 | $36.42B | $36.42B – $36.42B | 1 |
